Breast cancer (all types)
Which page is mine?
Loading
Type the words you were given: the cancer, the drug, the gene, or the phrase from the report you did not understand. Every page is in plain English first, with the technical layer one click below and a source under every number.
Three things worth reading before the next appointment. None of them asks you to understand the biology first.
What happens, in what order, and what to sort out while you wait. Written for 6 cancers so far.
The symptoms that mean ring tonight rather than wait, on the page for the cancer you have. Spinal cord compression, infection during chemotherapy, and the ones nobody warns you about.
Open your cancer's page, then the section called When to call.
Questions grouped by who you are seeing, each with the reason it is worth asking and the guideline or trial behind it. Take them in on a phone.
The commonest cancers, each with the sentence that tells you which of its pages you are on. Everything below a family page is one click down.
Which page is mine?
Which page is mine?
Lung cancer splits into non-small-cell disease, about 85 percent of it, and small-cell disease, which was 6.6 percent of English cases in 2024 and 9.1 percent of Welsh ones (National Lung Cancer Audit, State of the Nation 2026); the two behave and are treated very differently. The subtype pages carry the detail; this page covers screening, staging and what the types share.
The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy.
Which page is mine?
Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change.
Each one takes what you already know and gives back what the guideline says, with the trial figures for what each choice costs. No score, no prediction.
An educational aid, not advice for your case. For a superficial or low-risk basal cell carcinoma there is a genuine choice, and it is usually summarised in a way that hides what is being traded. Answer four questions and this sets out, for your situation, what the randomised trials found about cure rate, about how the result looks, and about what each treatment does to your skin while it works, quoted word for word with the study it came from. It gives no score and makes no prediction about you.
Basal cell carcinoma · follows Thomson et al., interventions for basal cell carcinoma of the skin (Cochrane Database of Systematic Reviews, 2020)
Answer five questions about the cancer and about what you want, and read the statements that apply, quoted word for word from NICE NG101 and from the trials that followed people for twenty years. An educational aid to prepare for the conversation with your surgeon, not advice, and not a prediction about you. Nothing you enter leaves this page.
Breast cancer (all types) · follows NICE NG101: early and locally advanced breast cancer, recommendations (2018, updated 2025)
Enter where the cancer was, the stage on your pathology report, what was given before the operation and whether oxaliplatin is suitable for you, and read the statements that apply, quoted word for word from NICE NG151. An educational aid to prepare for the conversation with your team, not advice. Nothing you enter leaves this page.
Colorectal cancer · follows NICE NG151: colorectal cancer, recommendations (January 2020, last updated December 2021)
Enter the polyp's size and shape, what earlier scans showed, and the risk factors the guideline names, and read the recommendation that applies, quoted word for word from the 2022 joint guideline of the European radiology, endoscopic surgery, digestive surgery and endoscopy societies. An educational aid to prepare for the conversation with your surgeon, not advice. Nothing you enter leaves this page.
Gallbladder cancer · follows Foley et al., Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE, European Radiology 2022
A gallbladder removed for stones has come back from the pathologist with a cancer in it. Enter the four items from the pathology and operation reports and read what the expert consensus, the UK systematic review, the timing study and the UK-wide CAPBIL series say for that combination, each quoted word for word, with the staging a second operation needs and the NHS route. An educational aid for the conversation with your surgeon, not advice. Nothing you enter leaves this page.
Gallbladder cancer · follows Aloia et al., Gallbladder cancer: expert consensus statement (AHPBA), HPB 2015
Enter the class the team gave your scan (resectable, borderline resectable, locally advanced or metastatic), whether you have jaundice, and how well you are, and read the statements that apply, quoted word for word from NICE NG85, the NICE appraisals and UK patient pages. An educational aid to prepare for the conversation with your team, not advice. Nothing you enter leaves this page.
Pancreatic ductal adenocarcinoma · follows NICE NG85: pancreatic cancer in adults, diagnosis and management, recommendations (February 2018, with later notes)
An educational aid, not advice for your case. Enter your Cambridge Prognostic Group and it shows what NICE NG131 offers at that group, word for word, together with NICE's own numbers for what each option did to survival, progression, continence, erections and bowels in a UK randomised trial.
Prostate cancer · follows NICE NG131: prostate cancer, diagnosis and management (May 2019, last updated 15 December 2021)
Enter the stage, what your breathing tests showed and whether you want an operation, and read the statements that apply, quoted word for word from NICE NG122. An educational aid to prepare for the conversation with your team, not advice. Nothing you enter leaves this page.
Non-small-cell lung cancer · follows NICE NG122: lung cancer, management (March 2019, last updated March 2024)
Enter what the pathology report at surgery showed, your germline BRCA result and whether pembrolizumab was part of the treatment before surgery, and read the statements that apply, quoted word for word from NICE, the trials and the residual cancer burden studies. An educational aid to prepare for the conversation with your oncologist, not advice. Nothing you enter leaves this page.
Triple-negative breast cancer (TNBC) · follows NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy, recommendation 1.1 (May 2023)
The same corpus, entered from a different question.
18,949 records, every fact dated and linked to a primary source. This is the scale of the thing, not the way in.